EQT Nears $10bn Deal for Qiagen
The private equity firm is in advanced talks to buy the molecular testing company, with KKR also bidding.
Updated on Nov. 5, 2026 in Biotech
EQT is in advanced negotiations to acquire Qiagen in a buyout valued above $10bn, and has reportedly made a binding offer exceeding $50 per share. KKR has also submitted a competing bid for the company.
Why it matters
Qiagen has been evaluating strategic alternatives amid renewed acquisition interest, and a deal would reshape ownership of a major molecular diagnostics provider. The competing bids signal strong investor appetite for life sciences tools and diagnostics companies.
The reported binding offer exceeds $50 per share, implying a valuation of approximately $10.2bn for the business. Terms remain unconfirmed, and the board has not yet announced a decision on either bid.
The players
EQT
EQT is a Swedish private equity firm that is in advanced negotiations to acquire Qiagen.
KKR
KKR is a global investment firm that has submitted a competing bid for Qiagen.
Qiagen
Qiagen is a molecular testing company listed in Frankfurt and the United States, serving clinical diagnostics and life sciences markets.
The details
Qiagen develops molecular testing technologies used in clinical diagnostics, pharmaceutical research and life sciences. Its board is scheduled to meet this week to consider a potential transaction, and Qiagen's US-listed shares rose following the report.
Timeline
January 2026: Bloomberg reported that Qiagen was considering its options.
November 3, 2026: Qiagen shares rose after the acquisition report.
This week: Qiagen's board is expected to meet to consider a potential transaction.
Market Landscape
The competing bids from EQT and KKR fit a broader pattern of private equity firms pursuing listed life sciences tools companies. Such deals consolidate diagnostics and research-tools assets under private ownership.
If the deal closes, Qiagen's diagnostic testing products used in clinical labs and research could come under new private ownership. Customers of its testing platforms may see changes in pricing or product direction under a new owner.
The takeaway
Competing private equity bids can push up valuations for listed diagnostics companies, which may benefit shareholders while leaving customers to watch for changes in how these tools are priced and supported.
What happens next
Qiagen's board is expected to meet this week to consider the potential transaction, which will determine whether talks advance to a definitive agreement.
Further reading
For related coverage of life sciences innovation, see Biotech.
